206 related articles for article (PubMed ID: 36098251)
1. Nanoparticle-Based Follistatin Messenger RNA Therapy for Reprogramming Metastatic Ovarian Cancer and Ameliorating Cancer-Associated Cachexia.
Korzun T; Moses AS; Kim J; Patel S; Schumann C; Levasseur PR; Diba P; Olson B; Rebola KGO; Norgard M; Park Y; Demessie AA; Eygeris Y; Grigoriev V; Sundaram S; Pejovic T; Brody JR; Taratula OR; Zhu X; Sahay G; Marks DL; Taratula O
Small; 2022 Nov; 18(44):e2204436. PubMed ID: 36098251
[TBL] [Abstract][Full Text] [Related]
2. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.
Zhong X; Narasimhan A; Silverman LM; Young AR; Shahda S; Liu S; Wan J; Liu Y; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2146-2161. PubMed ID: 35510530
[TBL] [Abstract][Full Text] [Related]
3. Development of ovarian tumour causes significant loss of muscle and adipose tissue: a novel mouse model for cancer cachexia study.
Luan Y; Zhang Y; Yu SY; You M; Xu PC; Chung S; Kurita T; Zhu J; Kim SY
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1289-1301. PubMed ID: 35044098
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
5. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice.
Bonetto A; Penna F; Minero VG; Reffo P; Bonelli G; Baccino FM; Costelli P
Curr Cancer Drug Targets; 2009 Aug; 9(5):608-16. PubMed ID: 19508174
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
7. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
8. RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice.
Pin F; Jones AJ; Huot JR; Narasimhan A; Zimmers TA; Bonewald LF; Bonetto A
J Bone Miner Res; 2022 Mar; 37(3):381-396. PubMed ID: 34904285
[TBL] [Abstract][Full Text] [Related]
9. Muscle myostatin signalling is enhanced in experimental cancer cachexia.
Costelli P; Muscaritoli M; Bonetto A; Penna F; Reffo P; Bossola M; Bonelli G; Doglietto GB; Baccino FM; Rossi Fanelli F
Eur J Clin Invest; 2008 Jul; 38(7):531-8. PubMed ID: 18578694
[TBL] [Abstract][Full Text] [Related]
10. Tumor inoculation site affects the development of cancer cachexia and muscle wasting.
Matsuyama T; Ishikawa T; Okayama T; Oka K; Adachi S; Mizushima K; Kimura R; Okajima M; Sakai H; Sakamoto N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Kokura S; Naito Y; Itoh Y
Int J Cancer; 2015 Dec; 137(11):2558-65. PubMed ID: 26016447
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle.
Han X; Møller LLV; De Groote E; Bojsen-Møller KN; Davey J; Henríquez-Olguin C; Li Z; Knudsen JR; Jensen TE; Madsbad S; Gregorevic P; Richter EA; Sylow L
J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1241-1257. PubMed ID: 31402604
[TBL] [Abstract][Full Text] [Related]
12. Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA.
Schumann C; Nguyen DX; Norgard M; Bortnyak Y; Korzun T; Chan S; Lorenz AS; Moses AS; Albarqi HA; Wong L; Michaelis K; Zhu X; Alani AWG; Taratula OR; Krasnow S; Marks DL; Taratula O
Theranostics; 2018; 8(19):5276-5288. PubMed ID: 30555546
[TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia.
Wang H; Lai YJ; Chan YL; Li TL; Wu CJ
Cancer Lett; 2011 Jun; 305(1):40-9. PubMed ID: 21397390
[TBL] [Abstract][Full Text] [Related]
14. Metabolic derangements of skeletal muscle from a murine model of glioma cachexia.
Cui P; Shao W; Huang C; Wu CJ; Jiang B; Lin D
Skelet Muscle; 2019 Jan; 9(1):3. PubMed ID: 30635036
[TBL] [Abstract][Full Text] [Related]
15. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia.
Fukawa T; Yan-Jiang BC; Min-Wen JC; Jun-Hao ET; Huang D; Qian CN; Ong P; Li Z; Chen S; Mak SY; Lim WJ; Kanayama HO; Mohan RE; Wang RR; Lai JH; Chua C; Ong HS; Tan KK; Ho YS; Tan IB; Teh BT; Shyh-Chang N
Nat Med; 2016 Jun; 22(6):666-71. PubMed ID: 27135739
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.
Reed SA; Sandesara PB; Senf SM; Judge AR
FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632
[TBL] [Abstract][Full Text] [Related]
17. Amiloride ameliorates muscle wasting in cancer cachexia through inhibiting tumor-derived exosome release.
Zhou L; Zhang T; Shao W; Lu R; Wang L; Liu H; Jiang B; Li S; Zhuo H; Wang S; Li Q; Huang C; Lin D
Skelet Muscle; 2021 Jul; 11(1):17. PubMed ID: 34229732
[TBL] [Abstract][Full Text] [Related]
18. Myostatin gene inactivation prevents skeletal muscle wasting in cancer.
Gallot YS; Durieux AC; Castells J; Desgeorges MM; Vernus B; Plantureux L; Rémond D; Jahnke VE; Lefai E; Dardevet D; Nemoz G; Schaeffer L; Bonnieu A; Freyssenet DG
Cancer Res; 2014 Dec; 74(24):7344-56. PubMed ID: 25336187
[TBL] [Abstract][Full Text] [Related]
19. Fuzheng Xiaoai Decoction 1 ameliorated cancer cachexia-induced muscle atrophy via Akt-mTOR pathway.
Cheng QQ; Mao SL; Yang LN; Chen L; Zhu JZ; Liu X; Hou AJ; Zhang RR
J Ethnopharmacol; 2023 Mar; 303():115944. PubMed ID: 36410574
[TBL] [Abstract][Full Text] [Related]
20. MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.
Judge SM; Deyhle MR; Neyroud D; Nosacka RL; D'Lugos AC; Cameron ME; Vohra RS; Smuder AJ; Roberts BM; Callaway CS; Underwood PW; Chrzanowski SM; Batra A; Murphy ME; Heaven JD; Walter GA; Trevino JG; Judge AR
Cancer Res; 2020 May; 80(9):1861-1874. PubMed ID: 32132110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
